Biosimilars is FDA approved for the treatment of rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis (JIA), psoriatic arthritis (PA), ankylosing spondylitis (AS), plaque psoriasis (PsO), inflammatory bowel disease (IBD): adult Crohn disease (CD), ulcerative colitis (UC), granulomatosis with polyangiitis (GPA) (Wegener granulomatosis), microscopic polyangiitis (MPA), type 1 diabetes mellitus (DM), non-squamous non-small cell lung cancer, metastatic colorectal cancer, metastatic renal cell carcinoma, glioblastoma, recurrent or metastatic cervical cancer, HER2 (human epidermal growth factor receptor 2) associated breast cancer, and HER2 associated gastric (metastatic) or gastroesophageal junction adenocarcinoma, chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL). Biosimilars are biotherapeutic agents similar to their respective original biologic product (reference product). This activity will highlight the mechanism of action, adverse event profile, and other key factors pertinent to interprofessional team members in managing patients with inflammatory diseases and the use of biosimilars.

**Objectives:**
- Identify the mechanism of action of all biosimilars.
- Identify the indications for the use of biosimilars.
- Identify the issues of concern that exist for biosimilars.
- Summarize interprofessional team strategies for improving care coordination and communication to advance biosimilars use in treating patients with inflammatory diseases and improve outcomes.